🇺🇸 FDA
Pipeline program

INC280, INC280, JNJ-61186372

61186372PANSC2001

Phase 2 small_molecule active

Quick answer

INC280, INC280, JNJ-61186372 for Unresectable Metastatic Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Unresectable Metastatic Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials